Clinical trial transparency regulations: Implications to various scholarly publishing stakeholders

As thousands of 2019 Corona virus disease (Covid-19) clinical trials are continuously getting added to various registries these days, good practices on data sharing and transparency have become one of the prime topics of discussion than ever before. Although trial registration is considered a crucial step, there is a lack of integration between registration and published literature. Trial outcomes are a matter of public interest, but sponsor compliances are not adequate with the recommended guidelines. Although the global recognition of data transparency increases day by day, there is still a long journey to travel. It is high time that scholarly publishing stakeholders should put in a collaborative effort to check author compliance. In this article, we aimed to comprehend and discuss the imperative roles of various scholarly publishing stakeholders in improving clinical trial transparency during this pandemic situation and highlight the changing paradigm towards the pressing need for reporting clinical trial data more effectively.